Health Minister Budi Gunadi Sadikin stated that Indonesia’s healthcare industry has the potential to grow independently without relying on foreign countries. He also emphasized that the national healthcare sector is capable of attracting substantial investment.

Speaking at CNBC Indonesia’s Economic Update 2026 event titled “Performance Achievements and Strategic Direction of Priority Ministry Programs” on Wednesday (24 June 2026), Budi explained that strengthening the healthcare industry initially stemmed from the need to build national health resilience and reduce dependence on imports. He noted that the Covid-19 pandemic demonstrated the risks of relying heavily on overseas supplies, as lockdowns disrupted imports.

According to him, investor interest in Indonesia’s healthcare industry is supported by the sector’s positive performance in recent years. National healthcare spending has reached around Rp640 trillion annually, with growth ranging between 9% and 11%.

Budi also revealed that the government is currently in discussions with a Japanese company planning to invest US$1 billion in Indonesia. He estimated that such an investment could ultimately generate around US$3 billion in gross domestic product (GDP).

In addition to the Japanese company, several international firms have shown interest in Indonesia’s healthcare sector, including General Electric, Aspen Medical, Swire Group, and SK Plasma. He added that Apollo Hospital has also approached the government regarding cooperation with Mayapada and plans to enter the Indonesian market. Meanwhile, domestic investors such as Astra and Djarum have already participated through investments in Hermina.

Beyond healthcare services, Indonesia’s domestic manufacturing capability for medical equipment has also continued to improve. The country is now able to produce various medical devices, including anthropometric equipment, ultrasound machines, vaccines, and CT scanners through partnerships with global companies.

As an example, General Electric is currently collaborating with Kalbe to establish a domestic CT scanner manufacturing industry, despite the complexity of the technology involved.

Meanwhile, for vaccine production, Indonesia currently has three local manufacturers: Bio Farma, Etana, and Biotis.